What protects Merck now: why access may matter more than price

The read: reach is becoming the moat

In short: Merck's protection is moving away from charging more and toward getting its drugs to more patients, faster, with the regulator's support. Its newest cardiovascular launch was priced for uptake, not for a premium.¹ Its best-known vaccine shows how far price increases can carry a franchise once demand softens.⁴

Merck & Co. ($MRK) is a drugmaker whose portfolio in the facts spans the GARDASIL vaccine, KEYTRUDA in lung cancer and an oral cholesterol-lowering drug.^4,5,3 For investors, the question is less whether Merck can raise prices and more whether it can defend volume, access and its place in the clinic. The evidence below comes almost entirely from Merck's own second-quarter earnings call.

LIPFENDRA: priced to spread, backed by the regulator

Merck priced LIPFENDRA to enable broad access, a strategy aimed at maximising uptake rather than premium pricing.¹ That is a deliberate trade: a lower price per patient in exchange for a larger base of patients and less friction with payers.

The regulatory side strengthens that choice. The FDA is using LIPFENDRA as a cornerstone to show its priority review goals, including public health impact, innovation, unmet need, onshoring and accessibility.⁶ A drug that a regulator holds up as its example has a kind of standing that is hard for a rival to copy quickly.

Distribution is the third leg. Plans are underway to place LIPFENDRA on TrumpRx as part of the MFN agreement.⁷ If that holds, it adds another route to patients, and it fits the broad-access pricing.

Separately, Merck has developed an oral PCSK9 inhibitor that achieves up to a 60% reduction in LDL cholesterol.³ A pill matters here because cholesterol treatment is long-term, and an oral option lowers the barrier for patients who would otherwise have to stay on therapy for years.

GARDASIL: what price can and cannot do

GARDASIL is the useful counterweight. U.S. sales were flat because of lower demand and the timing of CDC purchases, largely offset by price increases.⁴ So the franchise held its revenue, but price did the work, not volume.

That matters for the moat. Price can cover a soft patch, but a franchise that leans on price while demand eases is drawing down its protection rather than adding to it. The timing of government purchases also makes quarterly results lumpy, so one flat quarter alone says less than the trend across several.

Put next to LIPFENDRA, the picture is consistent. Merck seems to understand that the newest products need reach first, while the mature ones can lean on pricing for a while.

KEYTRUDA's next act and the partners around it

The deepest moat in oncology is owning the standard of care, and Merck is weighing a test of its own. The company is considering a head-to-head trial of sac-TMT plus pembro against KEYNOTE-189, the KEYTRUDA plus chemotherapy regimen, in first-line non-small cell lung cancer.⁵

Running a trial against your own standard is a lifecycle move. If the new combination beats the old one, the franchise moves to the next regimen without handing the slot to a competitor. If it falls short, the existing standard still stands, but the read-through would weigh on the pipeline story.

Partnerships widen the base too. Gilead is a collaborator on the Phase III ISLEND-1 and 2 trials testing islatravir and lenacapavir.⁸ Late-stage trials with an established partner spread the cost and risk, and they extend Merck's reach into areas outside oncology and cardiovascular.

How peers defend the same ground

The peer facts point the same way: access and clinical data are where the moats are being built. Johnson & Johnson says ICOTYDE has broad commercial access and preferred access on all national commercial plans, with expansion to Medicaid and Medicare underway.⁹ Its INLEXZO delivers high, durable complete remission rates in non-muscle invasive bladder cancer, which the company says supports its value.¹⁰

Novartis reports that LEQVIO holds a 23.3% share of the U.S. Medicare Part B segment, up 3.6% year to date, which it reads as sustained pricing and access strength.¹¹ That is the benchmark for the access playbook: share gains inside a government channel.

Pfizer, which leads our score, defends with prescription leadership and internal discovery. It sees the oral CGRP class as competitive, with NURTEC leading in total prescriptions.² It is developing atirmociclib, an internally discovered CDK4/6 inhibitor, and sees patients with obesity and related conditions as a key group for its berobenatide programme.^12,13

Merck sits second in our score, and its edge in the facts is a different mix: regulator standing for LIPFENDRA, a pricing choice built for reach, and lifecycle trials around KEYTRUDA.^1,6,5

What to watch next

The access thesis is testable, and the next few quarters will show it. First, LIPFENDRA uptake: broad-access pricing only pays if volume follows, so watch how management describes adoption and the progress of the TrumpRx listing.^1,7

Second, GARDASIL demand. A return of U.S. volume would ease the reliance on price increases. Another flat quarter carried by price would show the franchise still drawing on pricing power.⁴

Third, whether the sac-TMT plus pembro head-to-head trial moves from consideration to commitment.⁵ That decision would show how Merck plans to carry its lung cancer position into the next regimen. Taken together, these three signals will show whether reach is building into a durable moat or only substituting for price.